drugset / Trial / NCT06641544
The Efficacy and Safety of Different Combination Regimens of Inetetamab in First-line Treatment of HER2 Positive Metastatic Breast Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is to explore the efficacy and safety of the first-line treatment of HER2 positive recurrent/metastatic breast cancer with Inetetamab combined with Pertuzumab or Pyrotinib combined with chemotherapy, hoping to have better clinical benefits and provide a new treatment mode for targeted treatment.
Timeline
- Start
- 2024-10-17
- Primary completion
- 2027-12-31
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pertuzumab | Monoclonal antibody | 420 mg | Intravenous |
| Subject | Pyrotinib | Small molecule | 400 mg | Oral |
| Background | Inetetamab | Monoclonal antibody | 6 mg/kg | Intravenous |